Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C27H29NO11 |
Molecular Weight | 543.5193 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]1(C[C@H](N)[C@@H](O)[C@H](C)O1)O[C@H]2C[C@@](O)(CC3=C(O)C4=C(C(=O)C5=C(OC)C=CC=C5C4=O)C(O)=C23)C(=O)CO
InChI
InChIKey=AOJJSUZBOXZQNB-VTZDEGQISA-N
InChI=1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,17-,22-,27-/m0/s1
Molecular Formula | C27H29NO11 |
Molecular Weight | 543.5193 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Epirubicin is an anthracycline cytotoxic agent, is a 4'-epi-isomer of doxorubicin. The compound is marketed by Pfizer under the trade name Ellence in the US. It is indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer. Although it is known that anthracyclines can interfere with a number of biochemical and biological functions within eukaryotic cells, the precise mechanisms of epirubicin’s cytotoxic and/or antiproliferative properties have not been completely elucidated. It is known, that epirubicin forms a complex with DNA by intercalation of its planar rings between nucleotide base pairs, with consequent inhibition of nucleic acid (DNA and RNA) and protein synthesis. Such intercalation triggers DNA cleavage by topoisomerase II, resulting in cytocidal activity. Epirubicin also inhibits DNA helicase activity, preventing the enzymatic separation of double-stranded DNA and interfering with replication and transcription. Epirubicin is also involved in oxidation/reduction reactions by generating cytotoxic free radicals.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2311221 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | ELLENCE Approved UseEpirubicin Hydrochloride Injection is indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer Launch Date1999 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
5.7 μg/mL |
60 mg/m² single, intravenous dose: 60 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
EPIRUBICIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
9.3 μg/mL |
150 mg/m² single, intravenous dose: 150 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
EPIRUBICIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.6 μg × h/mL |
60 mg/m² single, intravenous dose: 60 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
EPIRUBICIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
4.2 μg × h/mL |
150 mg/m² single, intravenous dose: 150 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
EPIRUBICIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
35.3 h |
60 mg/m² single, intravenous dose: 60 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
EPIRUBICIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
31.1 h |
150 mg/m² single, intravenous dose: 150 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
EPIRUBICIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
23% |
60 mg/m² single, intravenous dose: 60 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: |
EPIRUBICIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
200 mg/m2 1 times / 3 weeks multiple, intravenous MTD Dose: 200 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 200 mg/m2, 1 times / 3 weeks Sources: Page: p.13,14 |
unhealthy, 31–62 n = 3 Health Status: unhealthy Condition: Ovarian carcinoma Age Group: 31–62 Sex: F Population Size: 3 Sources: Page: p.13,14 |
DLT: Thrombocytopenia, Leukopenia... Dose limiting toxicities: Thrombocytopenia (grade 4, 67%) Sources: Page: p.13,14Leukopenia (grade 4, 67%) Myelosuppression (grade 4, 100%) Stomatitis (grade 3, 33%) |
95 mg/m2 1 times / day multiple, intravenous Overdose Dose: 95 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 95 mg/m2, 1 times / day Sources: Page: p.11 |
unhealthy, 36 n = 1 Health Status: unhealthy Condition: non-Hodgkin’s lymphoma Age Group: 36 Sex: M Population Size: 1 Sources: Page: p.11 |
Disc. AE: Aplasia bone marrow, Mucositis... AEs leading to discontinuation/dose reduction: Aplasia bone marrow Sources: Page: p.11Mucositis (grade 4) Gastrointestinal bleeding |
320 mg/m2 single, intravenous Overdose Dose: 320 mg/m2 Route: intravenous Route: single Dose: 320 mg/m2 Sources: Page: p.11 |
unhealthy, 63 n = 1 Health Status: unhealthy Condition: Breast cancer and liver metastasis Age Group: 63 Sex: F Population Size: 1 Sources: Page: p.11 |
Disc. AE: Hyperthermia, Multiple organ failure... AEs leading to discontinuation/dose reduction: Hyperthermia Sources: Page: p.11Multiple organ failure Lactic acidosis Lactate dehydrogenase increased Anuria |
120 mg/m2 1 times / 3 weeks multiple, intravenous Recommended Dose: 120 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 120 mg/m2, 1 times / 3 weeks Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Axillary node tumor involvement following resection of primary breast cancer Sources: Page: p.1 |
Disc. AE: Soft tissue necrosis... AEs leading to discontinuation/dose reduction: Soft tissue necrosis (severe) Sources: Page: p.1 |
120 mg/m2 1 times / 3 weeks multiple, intravenous Recommended Dose: 120 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 120 mg/m2, 1 times / 3 weeks Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Axillary node tumor involvement following resection of primary breast cancer Sources: Page: p.1 |
DLT: Leukopenia, Neutropenia... Disc. AE: Toxic myocarditis, Congestive heart failure... Dose limiting toxicities: Leukopenia AEs leading toNeutropenia discontinuation/dose reduction: Toxic myocarditis (severe) Sources: Page: p.1Congestive heart failure (grade 3-5) Acute promyelocytic leukemia Myelosuppression (severe) Hyperuricemia Thrombophlebitis Thromboembolic event Pulmonary embolism |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Stomatitis | grade 3, 33% DLT, Disc. AE |
200 mg/m2 1 times / 3 weeks multiple, intravenous MTD Dose: 200 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 200 mg/m2, 1 times / 3 weeks Sources: Page: p.13,14 |
unhealthy, 31–62 n = 3 Health Status: unhealthy Condition: Ovarian carcinoma Age Group: 31–62 Sex: F Population Size: 3 Sources: Page: p.13,14 |
Myelosuppression | grade 4, 100% DLT, Disc. AE |
200 mg/m2 1 times / 3 weeks multiple, intravenous MTD Dose: 200 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 200 mg/m2, 1 times / 3 weeks Sources: Page: p.13,14 |
unhealthy, 31–62 n = 3 Health Status: unhealthy Condition: Ovarian carcinoma Age Group: 31–62 Sex: F Population Size: 3 Sources: Page: p.13,14 |
Leukopenia | grade 4, 67% DLT, Disc. AE |
200 mg/m2 1 times / 3 weeks multiple, intravenous MTD Dose: 200 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 200 mg/m2, 1 times / 3 weeks Sources: Page: p.13,14 |
unhealthy, 31–62 n = 3 Health Status: unhealthy Condition: Ovarian carcinoma Age Group: 31–62 Sex: F Population Size: 3 Sources: Page: p.13,14 |
Thrombocytopenia | grade 4, 67% DLT, Disc. AE |
200 mg/m2 1 times / 3 weeks multiple, intravenous MTD Dose: 200 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 200 mg/m2, 1 times / 3 weeks Sources: Page: p.13,14 |
unhealthy, 31–62 n = 3 Health Status: unhealthy Condition: Ovarian carcinoma Age Group: 31–62 Sex: F Population Size: 3 Sources: Page: p.13,14 |
Aplasia bone marrow | Disc. AE | 95 mg/m2 1 times / day multiple, intravenous Overdose Dose: 95 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 95 mg/m2, 1 times / day Sources: Page: p.11 |
unhealthy, 36 n = 1 Health Status: unhealthy Condition: non-Hodgkin’s lymphoma Age Group: 36 Sex: M Population Size: 1 Sources: Page: p.11 |
Gastrointestinal bleeding | Disc. AE | 95 mg/m2 1 times / day multiple, intravenous Overdose Dose: 95 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 95 mg/m2, 1 times / day Sources: Page: p.11 |
unhealthy, 36 n = 1 Health Status: unhealthy Condition: non-Hodgkin’s lymphoma Age Group: 36 Sex: M Population Size: 1 Sources: Page: p.11 |
Mucositis | grade 4 Disc. AE |
95 mg/m2 1 times / day multiple, intravenous Overdose Dose: 95 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 95 mg/m2, 1 times / day Sources: Page: p.11 |
unhealthy, 36 n = 1 Health Status: unhealthy Condition: non-Hodgkin’s lymphoma Age Group: 36 Sex: M Population Size: 1 Sources: Page: p.11 |
Anuria | Disc. AE | 320 mg/m2 single, intravenous Overdose Dose: 320 mg/m2 Route: intravenous Route: single Dose: 320 mg/m2 Sources: Page: p.11 |
unhealthy, 63 n = 1 Health Status: unhealthy Condition: Breast cancer and liver metastasis Age Group: 63 Sex: F Population Size: 1 Sources: Page: p.11 |
Hyperthermia | Disc. AE | 320 mg/m2 single, intravenous Overdose Dose: 320 mg/m2 Route: intravenous Route: single Dose: 320 mg/m2 Sources: Page: p.11 |
unhealthy, 63 n = 1 Health Status: unhealthy Condition: Breast cancer and liver metastasis Age Group: 63 Sex: F Population Size: 1 Sources: Page: p.11 |
Lactate dehydrogenase increased | Disc. AE | 320 mg/m2 single, intravenous Overdose Dose: 320 mg/m2 Route: intravenous Route: single Dose: 320 mg/m2 Sources: Page: p.11 |
unhealthy, 63 n = 1 Health Status: unhealthy Condition: Breast cancer and liver metastasis Age Group: 63 Sex: F Population Size: 1 Sources: Page: p.11 |
Lactic acidosis | Disc. AE | 320 mg/m2 single, intravenous Overdose Dose: 320 mg/m2 Route: intravenous Route: single Dose: 320 mg/m2 Sources: Page: p.11 |
unhealthy, 63 n = 1 Health Status: unhealthy Condition: Breast cancer and liver metastasis Age Group: 63 Sex: F Population Size: 1 Sources: Page: p.11 |
Multiple organ failure | Disc. AE | 320 mg/m2 single, intravenous Overdose Dose: 320 mg/m2 Route: intravenous Route: single Dose: 320 mg/m2 Sources: Page: p.11 |
unhealthy, 63 n = 1 Health Status: unhealthy Condition: Breast cancer and liver metastasis Age Group: 63 Sex: F Population Size: 1 Sources: Page: p.11 |
Soft tissue necrosis | severe Disc. AE |
120 mg/m2 1 times / 3 weeks multiple, intravenous Recommended Dose: 120 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 120 mg/m2, 1 times / 3 weeks Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Axillary node tumor involvement following resection of primary breast cancer Sources: Page: p.1 |
Leukopenia | DLT, Disc. AE | 120 mg/m2 1 times / 3 weeks multiple, intravenous Recommended Dose: 120 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 120 mg/m2, 1 times / 3 weeks Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Axillary node tumor involvement following resection of primary breast cancer Sources: Page: p.1 |
Neutropenia | DLT, Disc. AE | 120 mg/m2 1 times / 3 weeks multiple, intravenous Recommended Dose: 120 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 120 mg/m2, 1 times / 3 weeks Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Axillary node tumor involvement following resection of primary breast cancer Sources: Page: p.1 |
Acute promyelocytic leukemia | Disc. AE | 120 mg/m2 1 times / 3 weeks multiple, intravenous Recommended Dose: 120 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 120 mg/m2, 1 times / 3 weeks Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Axillary node tumor involvement following resection of primary breast cancer Sources: Page: p.1 |
Hyperuricemia | Disc. AE | 120 mg/m2 1 times / 3 weeks multiple, intravenous Recommended Dose: 120 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 120 mg/m2, 1 times / 3 weeks Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Axillary node tumor involvement following resection of primary breast cancer Sources: Page: p.1 |
Pulmonary embolism | Disc. AE | 120 mg/m2 1 times / 3 weeks multiple, intravenous Recommended Dose: 120 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 120 mg/m2, 1 times / 3 weeks Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Axillary node tumor involvement following resection of primary breast cancer Sources: Page: p.1 |
Thromboembolic event | Disc. AE | 120 mg/m2 1 times / 3 weeks multiple, intravenous Recommended Dose: 120 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 120 mg/m2, 1 times / 3 weeks Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Axillary node tumor involvement following resection of primary breast cancer Sources: Page: p.1 |
Thrombophlebitis | Disc. AE | 120 mg/m2 1 times / 3 weeks multiple, intravenous Recommended Dose: 120 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 120 mg/m2, 1 times / 3 weeks Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Axillary node tumor involvement following resection of primary breast cancer Sources: Page: p.1 |
Congestive heart failure | grade 3-5 Disc. AE |
120 mg/m2 1 times / 3 weeks multiple, intravenous Recommended Dose: 120 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 120 mg/m2, 1 times / 3 weeks Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Axillary node tumor involvement following resection of primary breast cancer Sources: Page: p.1 |
Myelosuppression | severe Disc. AE |
120 mg/m2 1 times / 3 weeks multiple, intravenous Recommended Dose: 120 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 120 mg/m2, 1 times / 3 weeks Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Axillary node tumor involvement following resection of primary breast cancer Sources: Page: p.1 |
Toxic myocarditis | severe Disc. AE |
120 mg/m2 1 times / 3 weeks multiple, intravenous Recommended Dose: 120 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 120 mg/m2, 1 times / 3 weeks Sources: Page: p.1 |
unhealthy Health Status: unhealthy Condition: Axillary node tumor involvement following resection of primary breast cancer Sources: Page: p.1 |
PubMed
Title | Date | PubMed |
---|---|---|
Docetaxel and epirubicin in advanced breast cancer. | 2001 |
|
Intensive cyclic chemotherapy with unprocessed whole blood support in advanced breast cancer. | 2001 |
|
Paclitaxel by 72-hour continuous infusion followed by bolus intravenous ifosfamide or epirubicin: results of two phase I studies. | 2001 |
|
Complete cure of malignant lymphoma of the stomach with a huge adrenal lesion achieved by preoperative chemotherapy and surgery: report of a case. | 2001 |
|
Thymidine labeling index analysis in early breast cancer patients randomized to receive perioperative chemotherapy. | 2001 |
|
Intensified chemotherapy supported by DMSO-free peripheral blood progenitor cells in breast cancer patients. | 2001 Apr |
|
Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study. | 2001 Apr |
|
[Early phase II study of amrubicin (SM-5887) for superficial bladder cancer: a dose-finding study for intravesical chemotherapy]. | 2001 Apr |
|
High-dose epirubicin plus docetaxel at standard dose with lenograstim support as first-line therapy in advanced breast cancer. | 2001 Apr |
|
Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer. | 2001 Apr |
|
Second-line therapy for potentially platinum-sensitive recurrent ovarian cancer: what is optimal treatment? | 2001 Apr |
|
Primary high-grade mucosa-associated lymphoid tissue-type lymphoma of the cervix presenting as a common endocervical polyp. | 2001 Apr |
|
Patterns of failure after induction chemotherapy and radiotherapy for locoregionally advanced nasopharyngeal carcinoma: the Queen Mary Hospital experience. | 2001 Apr 1 |
|
Expression and prognostic significance of catalase in malignant mesothelioma. | 2001 Apr 1 |
|
Ondansetron plus metopimazine compared with ondansetron plus metopimazine plus prednisolone as antiemetic prophylaxis in patients receiving multiple cycles of moderately emetogenic chemotherapy. | 2001 Apr 1 |
|
Differential anthracycline sensitivity in two related human colon carcinoma cell lines expressing similar levels of P-glycoprotein. | 2001 Apr 10 |
|
Dose-dense sequential chemotherapy with epirubicin and paclitaxel versus the combination, as first-line chemotherapy, in advanced breast cancer: a randomized study conducted by the Hellenic Cooperative Oncology Group. | 2001 Apr 15 |
|
Preoperative high-dose chemotherapy with peripheral blood stem cell support as a primary management of locally advanced breast cancer. | 2001 Feb |
|
The gemcitabine/epirubicin/paclitaxel trials in advanced breast cancer. | 2001 Feb |
|
Bone marrow involvement by nasal NK cell lymphoma at diagnosis is uncommon. | 2001 Feb |
|
Interferon alfa 2b as maintenance therapy in poor risk diffuse large B-cell lymphoma in complete remission after intensive CHOP-BLEO regimens. | 2001 Feb |
|
Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. | 2001 Feb 1 |
|
Anthracycline adjuvant chemotherapy: how much is enough? | 2001 Feb 1 |
|
Thymidine kinase and thymidylate synthase in advanced breast cancer: response to tamoxifen and chemotherapy. | 2001 Feb 15 |
|
High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC). | 2001 Jan |
|
Generalised seizures following ondansetron. | 2001 Jan |
|
[MR mammography of response-control in primary chemo-brachytherapy in BCT-inoperable breast cancer]. | 2001 Jan |
|
Reversal of multidrug resistance to epirubicin by cyclosporin A in liposomes or intralipid. | 2001 Jan-Feb |
|
Synchronous gastric adenocarcinoma and MALT lymphoma in a patient with H. pylori infection. Could the two neoplasms share a common pathogenesis? | 2001 Jan-Feb |
|
Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting. | 2001 Jun |
|
Metastatic eccrine porocarcinoma: response to docetaxel (Taxotere) chemotherapy. | 2001 Mar |
|
Impact of chemotherapy dose-density on radiotherapy dose-intensity after breast conserving surgery. | 2001 Mar |
|
High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel. | 2001 Mar |
|
Effective treatment with rituximab in a patient with refractory prolymphocytoid transformed B-chronic lymphocytic leukemia and Evans syndrome. | 2001 Mar |
|
A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule. | 2001 Mar |
|
[Long-term survival of a patient with postoperative liver metastasis of stage IVa gallbladder cancer responding to hepatic arterial infusion chemotherapy]. | 2001 Mar |
|
Efficacy of vinorelbine, epirubicin and prednisone combination regimen in pretreated elderly patients with aggressive non-Hodgkin's lymphoma. | 2001 Mar |
|
Paclitaxel sensitization of multidrug-resistant cells to chemotherapy is independent of the cell cycle. | 2001 Mar 1 |
|
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | 2001 Mar 15 |
|
Docetaxel and epirubicin plus G-CSF as mobilizing treatment to support high-dose chemotherapy in breast cancer. | 2001 Mar-Apr |
|
Epirubicin/taxane combinations in breast cancer: experience from several Italian trials. | 2001 May |
|
Dose-dense and sequential strategies in adjuvant breast cancer therapy. | 2001 May |
|
Kinetics of PBPC mobilization by cyclophosphamide, as compared with that by epirubicin/paclitaxel followed by G-CSF support: implications for optimal timing of PBPC harvest. | 2001 May |
|
Peripheral blood progenitor cell collection after epirubicin, paclitaxel, and cisplatin combination chemotherapy using EPO-based cytokine regimens: a randomized comparison of G-CSF and sequential GM-/G-CSF. | 2001 May |
|
The multimodality treatment of thymic carcinoma. | 2001 May |
|
Analysis of treatment failures and survival of patients with fallopian tube carcinoma: a cooperation task force (CTF) study. | 2001 May |
|
Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7. | 2001 May |
|
Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. | 2001 May 15 |
|
Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma. | 2001 May 15 |
|
Telomere length in breast cancer patients before and after chemotherapy with or without stem cell transplantation. | 2001 May 18 |
Sample Use Guides
Injection is administered to patients by intravenous infusion. Drug is given in 14 repeated 3- to 4-week cycles. The total dose may be given on Day 1 of each cycle 15 or divided equally and given on Days 1 and 8 of each cycle. The recommended starting dose is 100 to 120 mg/m2.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27158340
It was investigated the effect of combined treatment with the anthracycline agent epirubicin (EPI) and NK cells on human breast cancer cells. NK cells were obtained by autologous adoptive cell transfer from breast cancer patients and amplified for 14 days in vitro. The cytotoxicity of NK cells against breast cancer cells was higher following EPI (5.0 μg/ml) pretreatment than without EPI pretreatment or application of EPI alone. The expression of NKG2D ligands [unique long 16-binding protein (ULBP) 1, ULBP2, and major histocompatibility complex class I-related chain A] in breast cancer cells was upregulated by pretreatment with EPI, which also increased the secretion of interferon-γ and tumor necrosis factor-α and expression of perforin and granzyme B in NK cells. These results indicate that EPI-NK cell treatment has synergistic cytotoxic effects against breast cancer cells, and suggest that anthracycline-based chemotherapy and NK cell-based immunotherapy can be combined for more effective breast cancer treatment.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:51:39 GMT 2023
by
admin
on
Fri Dec 15 15:51:39 GMT 2023
|
Record UNII |
3Z8479ZZ5X
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LIVERTOX |
NBK548622
Created by
admin on Fri Dec 15 15:51:39 GMT 2023 , Edited by admin on Fri Dec 15 15:51:39 GMT 2023
|
||
|
NDF-RT |
N0000000176
Created by
admin on Fri Dec 15 15:51:39 GMT 2023 , Edited by admin on Fri Dec 15 15:51:39 GMT 2023
|
||
|
NDF-RT |
N0000007530
Created by
admin on Fri Dec 15 15:51:39 GMT 2023 , Edited by admin on Fri Dec 15 15:51:39 GMT 2023
|
||
|
FDA ORPHAN DRUG |
588517
Created by
admin on Fri Dec 15 15:51:39 GMT 2023 , Edited by admin on Fri Dec 15 15:51:39 GMT 2023
|
||
|
WHO-ATC |
L01DB03
Created by
admin on Fri Dec 15 15:51:39 GMT 2023 , Edited by admin on Fri Dec 15 15:51:39 GMT 2023
|
||
|
NDF-RT |
N0000175414
Created by
admin on Fri Dec 15 15:51:39 GMT 2023 , Edited by admin on Fri Dec 15 15:51:39 GMT 2023
|
||
|
FDA ORPHAN DRUG |
121498
Created by
admin on Fri Dec 15 15:51:39 GMT 2023 , Edited by admin on Fri Dec 15 15:51:39 GMT 2023
|
||
|
WHO-VATC |
QL01DB03
Created by
admin on Fri Dec 15 15:51:39 GMT 2023 , Edited by admin on Fri Dec 15 15:51:39 GMT 2023
|
||
|
NCI_THESAURUS |
C1594
Created by
admin on Fri Dec 15 15:51:39 GMT 2023 , Edited by admin on Fri Dec 15 15:51:39 GMT 2023
|
||
|
NDF-RT |
N0000007530
Created by
admin on Fri Dec 15 15:51:39 GMT 2023 , Edited by admin on Fri Dec 15 15:51:39 GMT 2023
|
||
|
NDF-RT |
N0000007530
Created by
admin on Fri Dec 15 15:51:39 GMT 2023 , Edited by admin on Fri Dec 15 15:51:39 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
5171
Created by
admin on Fri Dec 15 15:51:39 GMT 2023 , Edited by admin on Fri Dec 15 15:51:39 GMT 2023
|
PRIMARY | |||
|
SUB06571MIG
Created by
admin on Fri Dec 15 15:51:39 GMT 2023 , Edited by admin on Fri Dec 15 15:51:39 GMT 2023
|
PRIMARY | |||
|
3995
Created by
admin on Fri Dec 15 15:51:39 GMT 2023 , Edited by admin on Fri Dec 15 15:51:39 GMT 2023
|
PRIMARY | RxNorm | ||
|
D015251
Created by
admin on Fri Dec 15 15:51:39 GMT 2023 , Edited by admin on Fri Dec 15 15:51:39 GMT 2023
|
PRIMARY | |||
|
56420-45-2
Created by
admin on Fri Dec 15 15:51:39 GMT 2023 , Edited by admin on Fri Dec 15 15:51:39 GMT 2023
|
PRIMARY | |||
|
6962
Created by
admin on Fri Dec 15 15:51:39 GMT 2023 , Edited by admin on Fri Dec 15 15:51:39 GMT 2023
|
PRIMARY | |||
|
m4948
Created by
admin on Fri Dec 15 15:51:39 GMT 2023 , Edited by admin on Fri Dec 15 15:51:39 GMT 2023
|
PRIMARY | Merck Index | ||
|
47898
Created by
admin on Fri Dec 15 15:51:39 GMT 2023 , Edited by admin on Fri Dec 15 15:51:39 GMT 2023
|
PRIMARY | |||
|
3Z8479ZZ5X
Created by
admin on Fri Dec 15 15:51:39 GMT 2023 , Edited by admin on Fri Dec 15 15:51:39 GMT 2023
|
PRIMARY | |||
|
DTXSID0022987
Created by
admin on Fri Dec 15 15:51:39 GMT 2023 , Edited by admin on Fri Dec 15 15:51:39 GMT 2023
|
PRIMARY | |||
|
C62028
Created by
admin on Fri Dec 15 15:51:39 GMT 2023 , Edited by admin on Fri Dec 15 15:51:39 GMT 2023
|
PRIMARY | |||
|
EPIRUBICIN
Created by
admin on Fri Dec 15 15:51:39 GMT 2023 , Edited by admin on Fri Dec 15 15:51:39 GMT 2023
|
PRIMARY | |||
|
1030
Created by
admin on Fri Dec 15 15:51:39 GMT 2023 , Edited by admin on Fri Dec 15 15:51:39 GMT 2023
|
PRIMARY | |||
|
3Z8479ZZ5X
Created by
admin on Fri Dec 15 15:51:39 GMT 2023 , Edited by admin on Fri Dec 15 15:51:39 GMT 2023
|
PRIMARY | |||
|
256942
Created by
admin on Fri Dec 15 15:51:39 GMT 2023 , Edited by admin on Fri Dec 15 15:51:39 GMT 2023
|
PRIMARY | |||
|
DB00445
Created by
admin on Fri Dec 15 15:51:39 GMT 2023 , Edited by admin on Fri Dec 15 15:51:39 GMT 2023
|
PRIMARY | |||
|
41867
Created by
admin on Fri Dec 15 15:51:39 GMT 2023 , Edited by admin on Fri Dec 15 15:51:39 GMT 2023
|
PRIMARY | |||
|
100000080474
Created by
admin on Fri Dec 15 15:51:39 GMT 2023 , Edited by admin on Fri Dec 15 15:51:39 GMT 2023
|
PRIMARY | |||
|
CHEMBL417
Created by
admin on Fri Dec 15 15:51:39 GMT 2023 , Edited by admin on Fri Dec 15 15:51:39 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
BINDER->LIGAND |
BINDING
|
||
|
TRANSPORTER -> SUBSTRATE | |||
|
SALT/SOLVATE -> PARENT | |||
|
TRANSPORTER -> SUBSTRATE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
MAJOR
|
||
|
METABOLITE -> PARENT |
The mean metabolite/parent AUC ratio is about 25% for 7-deoxydoxorubicin aglycone
|
||
|
METABOLITE -> PARENT |
The mean metabolite/parent AUC ratio is about 15% for doxorubicin aglycone
|
||
|
METABOLITE -> PARENT |
The mean metabolite/parent AUC ratio is about 20% for epirubicin glucuronide
MAJOR
PLASMA
|
||
|
METABOLITE -> PARENT |
The mean metabolite/parent AUC ratio is about 25% for epirubicinol glucuronide
|
||
|
METABOLITE -> PARENT |
The mean metabolite/parent AUC ratio is about 4% 7-deoxydoxorubicinol aglycone
|
||
|
METABOLITE -> PARENT |
The mean metabolite/parent AUC ratio is about 15% for doxorubicinol aglycone
|
||
|
PRODRUG -> METABOLITE ACTIVE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||
Volume of Distribution | PHARMACOKINETIC |
|
|
|||